- Title: Subtitle
- Phase 1b/2a Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy–Induced Oral Mucositis (OM) in Patients With Oral Cavity or Oropharyngeal Carcinoma (OCC)
- Creators
- C.M. Anderson - University of IowaB.G. Allen - University of IowaW. Sun - University of IowaC.M. Lee - Cancer Care NorthwestS. Agarwala - St. Luke's HospitalM. Venigalla - Lakeland Regional Medical CenterL. Greenberg - Allegheny General HospitalD. Adkins - Washington University in St. LouisY. Chen - University of RochesterW. Zhen - University of Nebraska Medical CenterD. Mould - Projections Research Inc., Phoenixville, PAJ. Holmlund - Galera Therapeutics, Inc., Malvern, PAJ. Brill - Galera Therapeutics, Inc., Malvern, PAS. Sonis - BioModels, Boston, MAJ. Buatti - University of Iowa
- Resource Type
- Abstract
- Publication Details
- International journal of radiation oncology, biology, physics, Vol.94(4), pp.869-870
- DOI
- 10.1016/j.ijrobp.2015.12.033
- ISSN
- 0360-3016
- eISSN
- 1879-355X
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 03/15/2016
- Academic Unit
- Radiation Oncology; Pharmacy Practice and Science; Neurosurgery; Otolaryngology
- Record Identifier
- 9984305128502771
Abstract
Phase 1b/2a Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy–Induced Oral Mucositis (OM) in Patients With Oral Cavity or Oropharyngeal Carcinoma (OCC)
International journal of radiation oncology, biology, physics, Vol.94(4), pp.869-870
03/15/2016
DOI: 10.1016/j.ijrobp.2015.12.033
Details
Metrics
17 Record Views